These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

120 related items for PubMed ID: 2353797

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Orally administered 4-aminopyridine improves clinical signs in multiple sclerosis.
    Davis FA, Stefoski D, Rush J.
    Ann Neurol; 1990 Feb; 27(2):186-92. PubMed ID: 2317014
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. 4-Aminopyridine is superior to 3,4-diaminopyridine in the treatment of patients with multiple sclerosis.
    Polman CH, Bertelsmann FW, de Waal R, van Diemen HA, Uitdehaag BM, van Loenen AC, Koetsier JC.
    Arch Neurol; 1994 Nov; 51(11):1136-9. PubMed ID: 7980110
    [Abstract] [Full Text] [Related]

  • 5. Sustained-release fampridine for symptomatic treatment of multiple sclerosis.
    Korenke AR, Rivey MP, Allington DR.
    Ann Pharmacother; 2008 Oct; 42(10):1458-65. PubMed ID: 18780812
    [Abstract] [Full Text] [Related]

  • 6. Potassium channel blockers in multiple sclerosis: neuronal Kv channels and effects of symptomatic treatment.
    Judge SI, Bever CT.
    Pharmacol Ther; 2006 Jul; 111(1):224-59. PubMed ID: 16472864
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Sustained release oral fampridine in the treatment of multiple sclerosis.
    Kachuck NJ.
    Expert Opin Pharmacother; 2009 Aug; 10(12):2025-35. PubMed ID: 19586420
    [Abstract] [Full Text] [Related]

  • 10. 4-Aminopyridine improves clinical signs in multiple sclerosis.
    Stefoski D, Davis FA, Faut M, Schauf CL.
    Ann Neurol; 1987 Jan; 21(1):71-7. PubMed ID: 2435223
    [Abstract] [Full Text] [Related]

  • 11. An open-labelled clinical and electrophysiological study of 3,4 diaminopyridine in the treatment of fatigue in multiple sclerosis.
    Sheean GL, Murray NM, Rothwell JC, Miller DH, Thompson AJ.
    Brain; 1998 May; 121 ( Pt 5)():967-75. PubMed ID: 9619197
    [Abstract] [Full Text] [Related]

  • 12. The current status of studies of aminopyridines in patients with multiple sclerosis.
    Bever CT.
    Ann Neurol; 1994 May; 36 Suppl():S118-21. PubMed ID: 8017870
    [Abstract] [Full Text] [Related]

  • 13. [Aminopyridines for symptomatic treatment of multiple sclerosis].
    Jensen HB, Stenager E, Ravnborg MH.
    Ugeskr Laeger; 2011 Dec 12; 173(50):3259-63. PubMed ID: 22153210
    [Abstract] [Full Text] [Related]

  • 14. Fampridine-SR in multiple sclerosis: a randomized, double-blind, placebo-controlled, dose-ranging study.
    Goodman AD, Cohen JA, Cross A, Vollmer T, Rizzo M, Cohen R, Marinucci L, Blight AR.
    Mult Scler; 2007 Apr 12; 13(3):357-68. PubMed ID: 17439905
    [Abstract] [Full Text] [Related]

  • 15. Sustained-release fampridine for multiple sclerosis.
    Bever CT, Judge SI.
    Expert Opin Investig Drugs; 2009 Jul 12; 18(7):1013-24. PubMed ID: 19548855
    [Abstract] [Full Text] [Related]

  • 16. No benefit of 3,4-diaminopyridine in essential tremor: a placebo-controlled crossover study.
    Lorenz D, Hagen K, Ufer M, Cascorbi I, Deuschl G, Volkmann J.
    Neurology; 2006 Jun 13; 66(11):1753-5. PubMed ID: 16769957
    [Abstract] [Full Text] [Related]

  • 17. High-dose cyclophosphamide for moderate to severe refractory multiple sclerosis.
    Gladstone DE, Zamkoff KW, Krupp L, Peyster R, Sibony P, Christodoulou C, Locher E, Coyle PK.
    Arch Neurol; 2006 Oct 13; 63(10):1388-93. PubMed ID: 16908728
    [Abstract] [Full Text] [Related]

  • 18. Dalfampridine (Ampyra) for MS.
    Med Lett Drugs Ther; 2010 Sep 20; 52(1347):73-4. PubMed ID: 20847716
    [No Abstract] [Full Text] [Related]

  • 19. Treatment with oral 3,4 diaminopyridine improves leg strength in multiple sclerosis patients: results of a randomized, double-blind, placebo-controlled, crossover trial.
    Bever CT, Anderson PA, Leslie J, Panitch HS, Dhib-Jalbut S, Khan OA, Milo R, Hebel JR, Conway KL, Katz E, Johnson KP.
    Neurology; 1996 Dec 20; 47(6):1457-62. PubMed ID: 8960727
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.